Biotech

All Articles

Vaxcyte climbs on 'stunning' 31-valent PCV gain versus Pfizer

.Vaxcyte introduced what analysts called "stunning" phase 1/2 data for its own 31-valent pneumococca...

Recursion's human brain condition test presents little evidence of efficiency

.Recursion has actually discovered with a very early examination of its tech-enabled method to drug ...

Acepodia, Pfizer click on all together for chemistry-based cell therapy

.Phone it a scenario of good chemistry: Acepodia, a biotech based upon Nobel Champion scientific res...

Praxis epilepsy drug reduces seizures in period 2 trial

.Practice Preciseness Medicines has actually scored another midphase succeed in epilepsy this year, ...

Three execs resign as Dyne messages combined data for DMD prospect

.After running away a medical grip several years back, Dyne Therapy has shown new stage 1/2 data for...

Arrowhead fires off phase 3 information in uncommon metabolic disease in advance of market clash with Ionis

.Arrowhead Pharmaceuticals has revealed its own hand in front of a possible showdown with Ionis, pos...

Pfizer, Valneva reveal lyme health condition try successful for second booster

.Pfizer and also Valneva might possess concerning 2 additional years to stand by just before they cr...

Fierce Biotech Managing Editor Ayla Ellison Talks Patronize Michelle Benz on the Future of Biotech.

.Allow's dive into a discussion along with Ayla Ellison, Brutal Biotech Managing Editor and Michelle...

New information demonstrate how Bayer's asundexian fell short to stop movements

.Bayer put on hold the phase 3 trial for its own element XIa prevention asundexian late in 2013 afte...

Sanofi's tolebrutinib falls short 2 of 3 late-stage MS trials

.Sanofi is still set on taking its a number of sclerosis (MS) med tolebrutinib to the FDA, execs hav...